Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | ESRRG | P62508 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14859224 | 0.83 | ALDH1A1 (0.77) | ALDH1A1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL14865706 | 0.78 | ALDH1A1 (0.65) | ALDH1A1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL14860324 | 0.77 | ALDH1A1 (0.69) | ALDH1A1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL14859488 | 0.77 | ALDH1A1 (0.64) | ALDH1A1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL14860134 | 0.77 | ALDH1A1 (0.59) | ALDH1A1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL2343610 | 0.76 | NPC1 (0.74) | ALDH1A1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL29661130 | 0.76 | NPC1 (0.74) | ALDH1A1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL14859859 | 0.76 | ALDH1A1 (0.58) | ALDH1A1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL2344164 | 0.75 | ALDH1A1 (0.71) | ALDH1A1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL5458000 | 0.74 | MEN1 (0.74) | ALDH1A1RAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2583962-A2 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | claimed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | claimed |
| EP-2583962-A2 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | UGP2, TPMT, UPP1 | ALDH1A1 1884/4885RAB9A 2456/4885SMN1; SMN2 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.